Ribomic

Ribomic EBIT Margin

The EBIT Margin (Operating Margin) of Ribomic (4591.T) as of Oct 30, 2026 is -40,237.73 %. In the previous year, EBIT Margin (Operating Margin) was -49,861.84 % — a change of -19.30% (higher).

EBIT Margin

-40,237.73 %

YoY

-19.30%

Last updated:

EBIT Margin (Operating Margin) of Ribomic is 2026 -40,237.73 % . EBIT Margin (Operating Margin) of Ribomic was 2025 -49,861.84 % . It decreases by -19.30% higher compared to the previous year.

Ribomic's operating (EBIT) margin stands at -40,237.7%, down from -1,348.0% several years earlier.

The Ribomic EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-1,390.29 JPY
Jan 1, 2019
-11,682.30 JPY
Jan 1, 2020
-753.45 JPY
Jan 1, 2021
-1,347.98 JPY
Jan 1, 2022
-2,160.59 JPY
Jan 1, 2023
-2,707.39 JPY
Jan 1, 2025
-49,861.84 JPY
Jan 1, 2026
-40,237.73 JPY
The Ribomic EBIT Margin history
YEAREBIT MarginYoY
-40,237.73 %-19.30%
-49,861.84 %+1,741.69%
-2,707.39 %+25.31%
-2,160.59 %+60.28%
-1,347.98 %+78.91%
-753.45 %-93.55%
-11,682.30 %+740.28%
-1,390.29 %+65.89%
-838.09 %+91.91%
-436.70 %-34,009.56%
1.29 %-100.33%
-390.47 %+15,917.04%
-2.44 %+20.25%
-2.03 %+79.18%
-1.13 %-48.65%
-2.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

EBIT Margin (Operating Margin) of Ribomic is -40,237.73 % in 2026.

EBIT Margin (Operating Margin) of Ribomic changed from -49,861.84 % to -40,237.73 %, representing a -19.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Ribomic since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Ribomic with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Ribomic

All Key Metrics — Ribomic